Grant: Discovery Grants Program - Individual
Simon Fraser University
$32,000.00
Marek's disease avian herpesvirus - Learning from differences
EF 2023-24
Résumé
Herpesviruses are large double-strand DNA viruses that cause disease in different animals. Marek's disease virus (MDV) is a highly oncogenic avian alphaherpesvirus. Marek's disease (MD) is characterized by CD4+ T-cell lymphomas in latently infected chicken cells. At $1-2B/year in worldwide costs, MD is one of the most significant chronic disease problem for the poultry industry. MDV shares many characteristics of herpesviruses, but its infection and vaccine action have several unique features. Taking advantage of these unique features, my long-term goal is to gain mechanistic insights into herpesvirus pathogenesis and vaccine prevention. My short-term goals are: 1) to investigate how MDV generates progeny virus from latency to better understand how herpesviruses replicate, and 2) elucidate how MD vaccines prevent lymphoma without eliminating virulent virus infection. All herpesviruses are able to establish latent infection in host cells. Upon stimulation, the latently infected herpesvirus is reactivated and resumes progeny virus production using a circularized genome as a template for the rolling-circle model of replication. This proposed model does not, however, explain how sufficient numbers of circularized templates are generated to support the explosive nature of virus reproduction. Aim 1: Unlike most other herpesviruses, the MDV genome integrates into host chromosomes during latency. I hypothesize alternate lengthening of telomere (ALT) is the mechanism by which the integrated MDV genome is excised prior to replication. Tumor cells use ALT to elongate telomere sequence to prevent senescence. During ALT telomere elongation, a circular partially double strand DNA is excised. I will use molecular biology methods such as RNAi and FISH to examine if ALT excises and circularizes the integrated MDV genome. If so, ALT may work in tandem with the rolling-circle model to create additional copies of circular virus genome templates for MDV as well as non-integrating herpesviruses. Aim 2: While other viral vaccines prevent disease by inducing adaptive immune responses to eliminate the virus, MD vaccines prevent lymphoma without eliminating virulent viral infection. MD vaccines prevent latently infected lymphocytes from expressing a viral protein, MEQ. MEQ is an MDV-encoded oncogene whose expression is essential for the oncogenesis. I hypothesize the MD vaccine eliminates the subset of T-cells that are capable of undergoing transformation by providing intranuclear environment for the expression of MDV MEQ. I will combine recombinant virus and proteomics techniques to test if MD vaccine eliminates these cells by immunologically stimulating prior to the virulent MDV challenge, rendering them incapable of expressing MEQ in latency. Elucidation of MDV pathogenesis and MD vaccine action mechanisms will provide essential evidence to make informed predictions regarding risk of future MD vaccine breaks and develop new anti-herpesvirus drugs.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2022-03680
Name nom
Niikura, Masahiro
Department département
Health Sciences
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2022
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Veterinary sciences
Research subject en
Biologie animale
Research subject fr
Médecine vétérinaire
Application title
Marek's disease avian herpesvirus - Learning from differences
Keyword
alternate lengthening of telomere; herpesvirus; lymphoma; Marek's disease virus; poultry; vaccine effect; virus replication
Application summary
Herpesviruses are large double-strand DNA viruses that cause disease in different animals. Marek's disease virus (MDV) is a highly oncogenic avian alphaherpesvirus. Marek's disease (MD) is characterized by CD4+ T-cell lymphomas in latently infected chicken cells. At $1-2B/year in worldwide costs, MD is one of the most significant chronic disease problem for the poultry industry. MDV shares many characteristics of herpesviruses, but its infection and vaccine action have several unique features. Taking advantage of these unique features, my long-term goal is to gain mechanistic insights into herpesvirus pathogenesis and vaccine prevention. My short-term goals are: 1) to investigate how MDV generates progeny virus from latency to better understand how herpesviruses replicate, and 2) elucidate how MD vaccines prevent lymphoma without eliminating virulent virus infection. All herpesviruses are able to establish latent infection in host cells. Upon stimulation, the latently infected herpesvirus is reactivated and resumes progeny virus production using a circularized genome as a template for the rolling-circle model of replication. This proposed model does not, however, explain how sufficient numbers of circularized templates are generated to support the explosive nature of virus reproduction. Aim 1: Unlike most other herpesviruses, the MDV genome integrates into host chromosomes during latency. I hypothesize alternate lengthening of telomere (ALT) is the mechanism by which the integrated MDV genome is excised prior to replication. Tumor cells use ALT to elongate telomere sequence to prevent senescence. During ALT telomere elongation, a circular partially double strand DNA is excised. I will use molecular biology methods such as RNAi and FISH to examine if ALT excises and circularizes the integrated MDV genome. If so, ALT may work in tandem with the rolling-circle model to create additional copies of circular virus genome templates for MDV as well as non-integrating herpesviruses. Aim 2: While other viral vaccines prevent disease by inducing adaptive immune responses to eliminate the virus, MD vaccines prevent lymphoma without eliminating virulent viral infection. MD vaccines prevent latently infected lymphocytes from expressing a viral protein, MEQ. MEQ is an MDV-encoded oncogene whose expression is essential for the oncogenesis. I hypothesize the MD vaccine eliminates the subset of T-cells that are capable of undergoing transformation by providing intranuclear environment for the expression of MDV MEQ. I will combine recombinant virus and proteomics techniques to test if MD vaccine eliminates these cells by immunologically stimulating prior to the virulent MDV challenge, rendering them incapable of expressing MEQ in latency. Elucidation of MDV pathogenesis and MD vaccine action mechanisms will provide essential evidence to make informed predictions regarding risk of future MD vaccine breaks and develop new anti-herpesvirus drugs.